dermatomyositis
Information
- Disease name
- dermatomyositis
- Disease ID
- DOID:10223
- Description
- "A myositis that results_in inflammation located_in muscle or located_in skin where a skin rash is often seen prior to the onset of muscle weakness. The disease may result from either a viral infection or an autoimmune reaction." [url:http\://en.wikipedia.org/wiki/Dermatomyositis, url:http\://www.myositis.org/learn-about-myositis/types-of-myositis/dermatomyositis]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT04723303 | Active, not recruiting | Early Phase 1 | Phase 1 Study of ULSC in Patients With Polymyositis (PM) and Dermatomyositis (DM) | October 6, 2021 | April 8, 2024 |
| NCT04044690 | Active, not recruiting | Phase 3 | A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of IgPro20 in Adults With Dermatomyositis (DM) | October 21, 2019 | November 2027 |
| NCT00001331 | Completed | Genetic and Family Studies of Inherited Muscle Diseases | May 1993 | March 2002 | |
| NCT00001421 | Completed | Phase 2 | Methimazole to Treat Polymyositis and Dermatomyositis | June 1995 | April 2001 |
| NCT00004357 | Completed | Phase 2 | Absorption of Corticosteroids in Children With Juvenile Dermatomyositis | September 1997 | February 2008 |
| NCT00005571 | Completed | Phase 2 | Safety and Effectiveness of h5G1.1-mAb for Dermatomyositis | April 2000 | December 2001 |
| NCT00010335 | Completed | Phase 1 | Pilot Study of Total Body Irradiation in Combination With Cyclophosphamide, Anti-thymocyte Globulin, and Autologous CD34-Selected Peripheral Blood Stem Cell Transplantation in Children With Refractory Autoimmune Disorders | November 2000 | May 2011 |
| NCT00033891 | Completed | Phase 2 | Infliximab (Remicade ) to Treat Dermatomyositis and Polymyositis | April 10, 2002 | May 20, 2010 |
| NCT00106184 | Completed | Phase 2 | Rituximab for the Treatment of Refractory Adult and Juvenile Dermatomyositis (DM) and Adult Polymyositis (PM) | March 2006 | August 2010 |
| NCT00112385 | Completed | Phase 1 | A Pilot Study of Etanercept in Dermatomyositis | March 2006 | June 2010 |
| NCT00213629 | Completed | N/A | myoARRAY and TcLandscape Analysis for the Diagnosis of Inflammatory Myopathies | November 2004 | July 2010 |
| NCT00335985 | Completed | Phase 3 | Efficacy and Safety Study of GB-0998 for Treatment of Steroid-resistant Polymyositis and Dermatomyositis (PM/DM) | June 2006 | March 2009 |
| NCT00341679 | Completed | Studies of the Natural History and Pathogenesis of Autoimmune/Connective Tissue Diseases | July 13, 2005 | ||
| NCT00504348 | Completed | Phase 2/Phase 3 | Investigation in Myositis-associated Pneumonitis of Prednisolone And Concomitant Tacrolimus | July 2007 | January 2011 |
| NCT00651040 | Completed | Phase 3 | Combined Treatment of Methotrexate + Glucocorticoids Versus Glucocorticoids Alone in Patients With PM and DM | May 2008 | November 2014 |
| NCT00866125 | Completed | Hand Function in Patients With Poly- or Dermatomyositis | April 2002 | August 2002 | |
| NCT01315938 | Completed | Phase 2 | Abatacept Treatment in Polymyositis and Dermatomyositis | January 2011 | November 28, 2013 |
| NCT00001265 | Completed | Study and Treatment of Inflammatory Muscle Diseases | January 10, 1992 | April 5, 2024 | |
| NCT01165008 | Completed | Phase 2/Phase 3 | Anakinra in Myositis | September 2003 | September 2008 |
| NCT00001261 | Completed | Phase 2 | Intravenousimmunoglobulin (IVIg) for the Treatment of Inflammatory Myopathies | May 1990 | July 2002 |
| NCT01415219 | Completed | Phase 2 | Efficacy of an Individual Rehabilitation Program in Polymyositis and Dermatomyositis | March 2008 | December 2013 |
| NCT01432613 | Completed | N/A | Diagnostic Accuracy of Whole Body Magnetic Resonance Imaging in Inflammatory Myopathies | December 22, 2010 | November 26, 2016 |
| NCT01734369 | Completed | Environmental Risk Factors for Myositis in Military Personnel | March 13, 2014 | ||
| NCT01813617 | Completed | Outcome in Patients With Recent Onset Polymyositis and Dermatomyositis | September 2010 | ||
| NCT01906372 | Completed | Phase 2 | Acthar in Treatment of Refractory Dermatomyositis and Polymyositis | September 2013 | May 2016 |
| NCT02043548 | Completed | Phase 2 | Tocilizumab in the Treatment of Refractory Polymyositis and Dermatomyositis | October 1, 2014 | July 31, 2019 |
| NCT02245841 | Completed | Phase 4 | Efficacy and Safety of H.P. Acthar Gel for the Treatment of Refractory Cutaneous Manifestations of Dermatomyositis | June 15, 2015 | July 14, 2021 |
| NCT02594735 | Completed | Phase 4 | Abatacept in Juvenile Dermatomyositis | November 2015 | October 22, 2021 |
| NCT02612857 | Completed | Phase 2 | Trial of IMO-8400 in Adult Patients With Dermatomyositis | November 2015 | June 2018 |
| NCT02728752 | Completed | Phase 3 | Study Evaluating Efficacy and Safety of Octagam 10% in Patients With Dermatomyositis (Idiopathic Inflammatory Myopathy) | February 27, 2017 | November 5, 2019 |
| NCT02880527 | Completed | Study of the Prevalence of Polymyositis and Dermatomyositis in Normandy | July 2014 | May 2016 | |
| NCT02971683 | Completed | Phase 3 | Trial to Evaluate the Efficacy and Safety of Abatacept in Combination With Standard Therapy Compared to Standard Therapy Alone in Improving Disease Activity in Adults With Active Idiopathic Inflammatory Myopathy | May 4, 2017 | August 2, 2022 |
| NCT03002649 | Completed | Phase 1 | Study of Tofacitinib in Refractory Dermatomyositis | January 2017 | September 30, 2020 |
| NCT03027674 | Completed | Early Phase 1 | Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary Raynaud | August 2016 | August 2016 |
| NCT03181893 | Completed | Phase 2 | A Study In Adults With Moderate To Severe Dermatomyositis | January 23, 2018 | November 28, 2022 |
| NCT03267277 | Completed | Phase 2/Phase 3 | Sodium Thiosulfate for Treatment of Calcinosis Associated With Juvenile and Adult Dermatomyositis | October 5, 2017 | November 9, 2023 |
| NCT03414086 | Completed | Predictor of Clinical Response to Acthar in Myositis | November 6, 2017 | July 30, 2022 | |
| NCT03813160 | Completed | Phase 3 | Trial to Evaluate Efficacy and Safety of Lenabasum in Dermatomyositis | December 17, 2018 | October 5, 2021 |
| NCT03817424 | Completed | Phase 1 | A Study to Evaluate VIB7734 in Participants With Systemic Lupus Erythematosus (SLE), Cutaneous Lupus Erythematosus (CLE), Sjogren's Syndrome, Systemic Sclerosis, Polymyositis, and Dermatomyositis | December 13, 2018 | July 20, 2020 |
| NCT03941184 | Completed | Spontaneous Coronary Artery Dissection (SCAD) and Autoimmunity | January 1, 1995 | November 10, 2020 | |
| NCT04033926 | Completed | Phase 2 | A Phase 2 Study of KZR-616 to Evaluate Safety and Efficacy in Patients With Active Polymyositis or Dermatomyositis | January 14, 2020 | April 6, 2022 |
| NCT04486261 | Completed | N/A | High-intensity Strength Training in Myositis | August 30, 2021 | January 1, 2023 |
| NCT04628936 | Completed | Phase 2 | Open-label Extension to the Phase 2 Crossover Study (PRESIDIO) Evaluating KZR-616 in Patients With PM and DM. | November 4, 2020 | June 12, 2023 |
| NCT04976140 | Completed | Phase 1/Phase 2 | Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or Dermatomyositis | December 15, 2021 | October 6, 2023 |
| NCT05192200 | Completed | Phase 2 | An Extension Study for Participants Who Have Completed the Treatment Period of a Qualifying Parent Study | December 20, 2021 | November 20, 2023 |
| NCT06002750 | Completed | Evaluation of Tp-e Interval and Tp-e/QT Ratio in Dermatomyositis and Analysis of Their Relationship With Inflammation | November 24, 2021 | November 24, 2022 | |
| NCT06438679 | Enrolling by invitation | Phase 4 | 3T Therapy in the Treatment of MDA5-positive Dermatomyositis | March 19, 2024 | December 2026 |
| NCT05495321 | Enrolling by invitation | Phase 3 | Interleukin-2 on Active Dermatomyositis | December 1, 2022 | September 1, 2026 |
| NCT06298019 | Not yet recruiting | Phase 1 | Study of KYV-101 Anti-CD19 CAR T Therapy in Adult Dermatomyositis | April 2024 | April 2039 |
| NCT06004817 | Not yet recruiting | Evaluation of Severity in Juvenile and Adult-onset Dermatomyositis | October 1, 2023 | September 30, 2024 | |
| NCT05637931 | Not yet recruiting | Plexin D1 as a Potential Biomarker inPM/DM | December 25, 2022 | January 25, 2024 | |
| NCT05488327 | Not yet recruiting | N/A | Lenalidomide in the Treatment of Refractory Cutaneous Dermatomyositis | August 1, 2022 | September 1, 2023 |
| NCT06433999 | Not yet recruiting | Phase 2 | A 12-Week Open-Label Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Skin-Predominant Dermatomyositis | June 2024 | January 2025 |
| NCT06284954 | Not yet recruiting | Phase 2 | A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis | September 2024 | January 20, 2028 |
| NCT06347718 | Recruiting | Phase 1/Phase 2 | CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease | July 17, 2023 | May 31, 2026 |
| NCT00017914 | Recruiting | Adult and Juvenile Myositis | June 7, 1995 | ||
| NCT05523167 | Recruiting | Phase 2/Phase 3 | A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy. | October 12, 2022 | February 1, 2027 |
| NCT03582800 | Recruiting | Phase 2 | Subcutaneous Injection of Sodium Thiosulfate for Ectopic Calcifications or Ossifications. A Pilot Study | January 6, 2020 | June 6, 2025 |
| NCT06056921 | Recruiting | Phase 1 | Safety and Efficacy of CD19 Targeted CAR-T Therapy for Refractory Autoimmune Disease | August 31, 2023 | August 31, 2026 |
| NCT03816345 | Recruiting | Phase 1 | Nivolumab in Treating Patients With Autoimmune Disorders and Advanced, Metastatic, or Unresectable Cancer | July 16, 2019 | August 31, 2024 |
| NCT06149039 | Recruiting | Study on Lymphocyte Subsets of Peripheral Blood in Patients With Nonmyopathic Dermatomyositis Complicated With Pulmonary Interstitial Disease | April 1, 2023 | June 30, 2024 | |
| NCT03840928 | Recruiting | PatientSpot Formerly Known as ArthritisPower | April 1, 2015 | March 1, 2025 | |
| NCT06154252 | Recruiting | Phase 1/Phase 2 | RESET-Myositis: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Idiopathic Inflammatory Myopathy | December 20, 2023 | July 2028 |
| NCT04402086 | Recruiting | Rheumatology Patient Registry and Biorepository | August 4, 2020 | June 1, 2030 | |
| NCT04972760 | Recruiting | Phase 3 | Baricitinib in Patients With Relapsing or naïve Dermatomyositis | August 31, 2022 | February 28, 2026 |
| NCT01276470 | Recruiting | Environmental Risk Factors for the Anti-synthetase Syndrome | February 9, 2011 | ||
| NCT05239702 | Recruiting | Early Phase 1 | Clinical Study of Targeting CD7 CAR-T Cells in the Treatment of Autoimmune Diseases | February 28, 2022 | December 1, 2024 |
| NCT05437263 | Recruiting | Phase 3 | A Study to Investigate the Efficacy and Safety of Brepocitinib in Adults With Dermatomyositis | October 31, 2022 | December 2024 |
| NCT03293615 | Recruiting | N/A | Exercise Capacity of Patients With Dermatomyosis | November 28, 2019 | January 1, 2025 |
| NCT05650567 | Recruiting | Phase 2 | Study of M5049 in DM and PM Participants (NEPTUNIA) | January 19, 2023 | December 4, 2024 |
| NCT02945345 | Recruiting | Clinical Responsiveness of Dermatomyositis Using Cutaneous Dermatomyositis Disease Area and Severity Index (CDASI) | June 2008 | January 2, 2025 | |
| NCT05695950 | Recruiting | Phase 2 | A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis | February 27, 2023 | March 2025 |
| NCT05832034 | Recruiting | Phase 2 | Add-on Intravenous Immunoglobulins in Early Myositis | September 13, 2021 | September 2024 |
| NCT05833711 | Recruiting | Phase 2 | Study Evaluating Efficacy and Safety of Froniglutide (PF1801) in Patients With Idiopathic Inflammatory Myopathy | September 5, 2023 | September 2025 |
| NCT05979441 | Recruiting | Phase 3 | A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Active Idiopathic Inflammatory Myopathy | September 12, 2023 | September 2027 |
| NCT06462768 | Recruiting | Neutrophil Extracellular Traps in Different Forms of Systemic Sclerosis | November 27, 2023 | April 27, 2029 | |
| NCT03686969 | Terminated | Phase 3 | Study Evaluating Efficacy and Safety of Octanorm in Patients With Dermatomyositis | August 2, 2018 | November 29, 2018 |
| NCT04999020 | Terminated | Phase 2/Phase 3 | Ravulizumab Versus Placebo in Adult Participants With Dermatomyositis | November 19, 2021 | May 8, 2024 |
| NCT02271165 | Terminated | Early Phase 1 | Subcutaneous Immunoglobulin (Hizentra) in Patients With Dermatomyositis: A Proof of Concept Study | November 2014 | March 2, 2017 |
| NCT00035958 | Terminated | Phase 2/Phase 3 | Understanding the Pathogenesis and Treatment of Childhood Onset Dermatomyositis | August 2002 | August 2002 |
| NCT02466243 | Terminated | Phase 2 | Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis | June 2015 | January 29, 2021 |
| NCT03981744 | Terminated | Phase 3 | A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments | July 26, 2019 | July 12, 2022 |
| NCT01140503 | Terminated | N/A | A Study to Evaluate the Safety and Efficacy of Apremilast in the Treatment of Skin Disease in Patients With Dermatomyositis | February 2010 | September 2011 |
| NCT01148810 | Terminated | Phase 2 | Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis | June 15, 2010 | June 13, 2012 |
| NCT03192657 | Unknown status | Phase 2 | Basiliximab Treating Interstitial Pneumonia of CADM | July 2017 | June 2020 |
| NCT04946669 | Unknown status | Early Phase 1 | An Exploratory Study on the Efficacy and Safety of Abatacept in the Treatment of Refractory Dermatomyositis | February 1, 2021 | July 31, 2022 |
| NCT04747652 | Unknown status | Clinical Research on Advanced Warning Factors Of Respiratory Injury in Dermatomyositis | June 1, 2020 | December 31, 2022 | |
| NCT05027152 | Unknown status | N/A | Muscle Function and Effects of Repetitive Task Training in Patients With Inflammatory Myopaties | September 1, 2021 | September 1, 2023 |
| NCT01637064 | Unknown status | Dermatomyositis and Polymyositis Registry | April 2013 | ||
| NCT03324152 | Unknown status | N/A | Effects of High-intensity Interval Training (HIIT) in Recent Onset Polymyositis and Dermatomyositis | October 1, 2017 | December 31, 2021 |
| NCT02980198 | Withdrawn | Phase 2 | Study of IFN-K in Dermatomyositis | May 3, 2017 | December 11, 2019 |
| NCT02418273 | Withdrawn | Phase 1/Phase 2 | Denosumab for Glucocorticoid-treated Children With Rheumatic Disorders | August 1, 2019 | June 2021 |
| NCT05361109 | Withdrawn | Phase 2 | Baricitinib for Cutaneous Dermatomyositis | June 1, 2022 | March 31, 2023 |
- Disase is a (Disease Ontology)
- DOID:633
- Cross Reference ID (Disease Ontology)
- GARD:6263
- Cross Reference ID (Disease Ontology)
- ICD10CM:M33
- Cross Reference ID (Disease Ontology)
- ICD9CM:710.3
- Cross Reference ID (Disease Ontology)
- MESH:D003882
- Cross Reference ID (Disease Ontology)
- NCI:C26744
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:38826005
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0011633
- Exact Synonym (Disease Ontology)
- dermatopolymyositis
- Exact Synonym (Disease Ontology)
- Polymyositis with skin involvement
- Disase Synonym (Disease Ontology)
- Amyopathic dermatomyositis
- OrphaNumber from OrphaNet (Orphanet)
- 221
- MedGen concept unique identifier (MedGen Concept name)
- C0011633
- MedGen unique identifier (MedGen Concept name)
- 8331
- MeSH unique ID (MeSH (Medical Subject Headings))
- D003882